Sadia H Sarzynski1, Sarah Warner1, Junfeng Sun1, Roland Matsouaka2,3, John P Dekker4, Ahmed Babiker5,6, Willy Li7, Yi Ling Lai1, Robert L Danner1, Vance G Fowler2,3, Sameer S Kadri1. 1. Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA. 2. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. 3. Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. 4. Bacterial Pathogenesis and Antimicrobial Resistance Unit, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA. 5. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 6. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 7. Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is considered first-line therapy for Stenotrophomonas maltophilia infections based on observational data from small studies. Levofloxacin has emerged as a popular alternative due to tolerability concerns related to TMP-SMX. Data comparing levofloxacin to TMP-SMX as targeted therapy are lacking. METHODS: Adult inpatient encounters January 2005 through December 2017 with growth of S maltophilia in blood and/or lower respiratory cultures were identified in the Cerner Healthfacts database. Patients included received targeted therapy with either levofloxacin or TMP-SMX. Overlap weighting was used followed by downstream weighted regression. The primary outcome was adjusted odds ratio (aOR) for in-hospital mortality or discharge to hospice. The secondary outcome was number of days from index S maltophilia culture to hospital discharge. RESULTS: Among 1581 patients with S maltophilia infections, levofloxacin (n = 823) displayed statistically similar mortality risk (aOR, 0.76 [95% confidence interval {CI}, .58-1.01]; P = .06) compared to TMP-SMX (n = 758). Levofloxacin (vs TMP-SMX) use was associated with a lower aOR of death in patients with lower respiratory tract infection (n = 1452) (aOR, 0.73 [95% CI, .54-.98]; P = .03) and if initiated empirically (n = 89) (aOR, 0.16 [95% CI, .03-.95]; P = .04). The levofloxacin cohort had fewer hospital days between index culture collection and discharge (weighted median [interquartile range], 7 [4-13] vs 9 [6-16] days; P < .0001). CONCLUSIONS: Based on observational evidence, levofloxacin is a reasonable alternative to TMP-SMX for the treatment of bloodstream and lower respiratory tract infections caused by S maltophilia.
BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is considered first-line therapy for Stenotrophomonas maltophilia infections based on observational data from small studies. Levofloxacin has emerged as a popular alternative due to tolerability concerns related to TMP-SMX. Data comparing levofloxacin to TMP-SMX as targeted therapy are lacking. METHODS: Adult inpatient encounters January 2005 through December 2017 with growth of S maltophilia in blood and/or lower respiratory cultures were identified in the Cerner Healthfacts database. Patients included received targeted therapy with either levofloxacin or TMP-SMX. Overlap weighting was used followed by downstream weighted regression. The primary outcome was adjusted odds ratio (aOR) for in-hospital mortality or discharge to hospice. The secondary outcome was number of days from index S maltophilia culture to hospital discharge. RESULTS: Among 1581 patients with S maltophilia infections, levofloxacin (n = 823) displayed statistically similar mortality risk (aOR, 0.76 [95% confidence interval {CI}, .58-1.01]; P = .06) compared to TMP-SMX (n = 758). Levofloxacin (vs TMP-SMX) use was associated with a lower aOR of death in patients with lower respiratory tract infection (n = 1452) (aOR, 0.73 [95% CI, .54-.98]; P = .03) and if initiated empirically (n = 89) (aOR, 0.16 [95% CI, .03-.95]; P = .04). The levofloxacin cohort had fewer hospital days between index culture collection and discharge (weighted median [interquartile range], 7 [4-13] vs 9 [6-16] days; P < .0001). CONCLUSIONS: Based on observational evidence, levofloxacin is a reasonable alternative to TMP-SMX for the treatment of bloodstream and lower respiratory tract infections caused by S maltophilia.
Authors: J-H Ko; C-I Kang; P Cornejo-Juárez; K-M Yeh; C-H Wang; S Y Cho; M G Gözel; S-H Kim; P-R Hsueh; N Sekiya; Y Matsumura; D-G Lee; S-Y Cho; S Shiratori; Y-J Kim; D R Chung; K R Peck Journal: Clin Microbiol Infect Date: 2018-11-16 Impact factor: 8.067
Authors: Mark A Toleman; Peter M Bennett; David M C Bennett; Ronald N Jones; Timothy R Walsh Journal: Emerg Infect Dis Date: 2007-04 Impact factor: 6.883
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo Journal: JAC Antimicrob Resist Date: 2022-05-05
Authors: Vidmantas Petraitis; Ruta Petraitiene; Povilas Kavaliauskas; Ethan Naing; Andrew Garcia; Benjamin N Georgiades; Roger Echols; Robert A Bonomo; Yoshinori Yamano; Michael J Satlin; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2022-09-26 Impact factor: 5.938